drugset
Drugs / FP9-PP
last change Apr 2007 re-read 3 minutes ago

FP9-PP

also known as FP9 polyprotein

Vaccine

Developed for
Plasmodium falciparum malaria
Investigated by
European Vaccine Initiative · University of Oxford · Wellcome Trust · Walter Reed Army Institute of Research (WRAIR)

Trials 2

today NCT00375128 · Ph 1/2 NCT00374998 · Ph 1
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT00374998 Apr 2006 → Jan 2007 Plasmodium falciparum malaria European Vaccine Initiative Completed No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT00375128 Sep 2006 → Apr 2007 Plasmodium falciparum malaria European Vaccine Initiative Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as FP9-PP ClinicalTrials.gov intervention name — accepted as the source's own label NCT00375128 ↗
1

NCT00374998 ↗
Known as FP9 polyprotein “FP9-PP (FP9 polyprotein)” NCT00374998 ↗
1

“FP9-PP (FP9 polyprotein)” NCT00375128 ↗
Modality Vaccine “two candidate malaria vaccines (FP9-PP and MVA-PP)” NCT00374998 ↗